Study of the effect of human placenta hydrolysate in a new model of metabolic-associated fatty liver disease with iron overload

Background. The combination of metabolic-associated fatty liver disease (МAFLD) with iron overload occurs in approximately 1/3 of patients and is extremely difficult to treat. In addition to the fact that no specific treatments have been developed for this МAFLD form, there are also few experimental...

Full description

Saved in:

Bibliographic Details
Main Authors:	T. E. Bogacheva, O. A. Gromova, I. Yu. Torshin, V. I. Demidov, A. G. Kalacheva, A. A. Garanin, I. V. Gogoleva, L. E. Fedotova, O. A. Limanova, А. N. Mnatsakanyan, N. Yu. Zhidomorov, T. R. Grishina
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2025-02-01
Series:	Фармакоэкономика
Subjects:	polyorgan pathology metabolic-associated fatty liver disease мafld iron overload fructose palm oil polypeptide therapy human placenta hydrolyzate hph
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/1118
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Study of the effect of human placenta hydrolysate in a new model of metabolic-associated fatty liver disease with iron overload

Similar Items